Immunotherapies

Emerging data suggest immunotherapies and novel peptides that target gut inflammation could serve as complementary agents to available diabetes drugs to more effectively target cardiometabolic diseases, according to a speaker.

Long-term exposure to immunotherapy reduced the rate of relapses and disability progression among a large cohort of patients with MS followed for 15 years, according to findings published in Neurology.